Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this special FDA-focused episode of Mind Moments, migraine expert Stewart Tepper, MD, professor of neurology at the Geisel School of Medicine at Dartmouth, discusses the recent FDA approvals of STS101 (Atzumi; Satsuma Pharmaceuticals) and CT-132 ( ) for the acute and preventive treatment of migraine. Tepper breaks down the pharmacological profile and clinical utility of DHE, the formulation behind STS101, and how the latest delivery innovations may expand its use in acute migraine care. He also dives into the approval data behind CT-132, the first-ever FDA-approved prescription digital therapeutic for migraine, and what it could mean for patients and clinicians alike. Tepper highlights the need for clinician education as novel therapeutics reshape the treatment landscape and offers insight into how these new tools could improve patient outcomes with fewer side effects and better accessibility.

For more of NeurologyLive's coverage of STS101 and CT-132 for migraine, head here: FDA Approves STS101 Nasal Powder as New Treatment for Acute Migraine

FDA Approves CT-132 as First Digital Therapeutic for Preventive Treatment of Episodic Migraine

Episode Breakdown:

1:10 – Overview of DHE, patient suitability, and STS101’s place in treatment

6:05 – Efficacy and safety data from the ASCEND and SUMMIT trials for STS101

10:20 – The expanding migraine toolbox and need for clinician education

15:10 – CT-132’s first-in-class status and clinical trial data

16:25 – Clinical use of CT-132 as an add-on preventive

19:30 – The knowledge gap on digital therapeutics and educating the neurology community

23:00 – Future directions and hopes for expanded CT-132 research

Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.